4.8 Article

Vitamin E (D-alpha-tocopheryl-co-poly(ethylene glycol) 1000 succinate) micelles-superparamagnetic iron oxide nanoparticles for enhanced thermotherapy and MRI

Journal

BIOMATERIALS
Volume 32, Issue 24, Pages 5663-5672

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2011.04.037

Keywords

Cancer nanotechnology; Colloidal stability; Magnetic micelles; Molecular imaging; Nanothermotherapy; Xenograft tumor model

Funding

  1. A*STAR, Singapore
  2. National University of Singapore (NUS)

Ask authors/readers for more resources

We synthesized vitamin E TPGS (D-alpha-Tocopheryl-co-poly(ethylene glycol) 1000 succinate) micelles for superparamagnetic iron oxides formulation for nanothermotherapy and magnetic resonance imaging (MRI), which showed better thermal and magnetic properties, and in vitro cellular uptake and lower cytotoxicity as well as better in vivo therapeutic and imaging effects in comparison with the commercial Resovist (R) and the Pluronic (R) F127 micelles reported in the recent literature. The superparamagnetic iron oxides originally coated with oleic acid and oleylamine were formulated in the core of the TPGS micelles using a simple solvent-exchange method. The IOs-loaded TPGS showed greatest colloidal stability due to the critical micelle concentration (CMC) of vitamin E TPGS. Highly monodisperse and water soluble suspension was obtained which were stable in 0.9% normal saline for a period of 12 days. The micelles were characterized for their size and size distribution. Their morphology was examined through transmission electron microscopy (TEM). The enhanced thermal and superparamagnetic properties of the IOs-loaded TPGS micelles were assessed. Cellular uptake and cytotoxicity were investigated in vitro with MCF-7 cancer cells. Relaxivity study showed that the IOs-loaded TPGS micelles can have better effects for T2-weighted imaging using MRI. 12 mapped images of xenograft grown on SCID mice showed that the TPGS micelle formulation of IOs had similar to 1.7 times and similar to 1.05 times T2 decrease at the tumor site compared to Resovist (R) and the F127 micelle formulation, respectively. (C) 2011 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available